China News Service, Guangzhou, August 22 (Cai Minjie Xu Yongyi) The Second Affiliated Hospital of Guangzhou Medical University, the yttrium-90 microsphere interventional therapy project for liver tumors was officially launched on the 22nd. Provide integrated precision diagnosis and treatment services for patients with liver metastases.
According to reports, liver malignancies include primary liver cancer and liver metastases.
As one of the malignant tumors with a high mortality rate in China, liver cancer has the characteristics of "high recurrence and easy metastasis" with insidious early symptoms.
The Chinese Guidelines for Diagnosis and Comprehensive Treatment of Colorectal Cancer Liver Metastasis (2020) show that in China, liver metastasis is an important cause of death in patients with colorectal cancer, and the 5-year survival rate of patients with unresectable liver metastases is less than 10%.
For malignant tumors, the introduction of safe and controllable radiopharmaceuticals into the tumor to destroy and kill the cancer cells is an effective solution.
Zhang Zhenhui, deputy dean of the Second Affiliated Hospital of Guangzhou Medical University, said that yttrium [90Y] resin microspheres are tiny spheres with the radioactive isotope yttrium [90Y], which emit pure beta rays with an average penetration distance in human tissues. It is only 2.5 mm and can be concentrated in the tumor. Its killing ability to tumor tissue is much higher than that of external radiation therapy, while the damage to normal tissue is small.
Yttrium [90Y] microsphere injection is a drug for the treatment of liver tumor lesions by delivering resin microspheres loaded with radioisotope yttrium [90Y] into liver tumor by means of vascular intervention.
According to reports, Yttrium [90Y] Microsphere Injection was approved by the State Drug Administration for marketing on February 9, 2022.
Before that, Yttrium [90Y] Microsphere Injection has been marketed in more than 50 countries and regions around the world, and has been used for more than 20 years, with a cumulative treatment of more than 120,000 times, and has been recommended by authoritative guidelines such as the European Society of Medical Oncology.
Individualized comprehensive treatment is the key to improving the long-term survival of patients with liver tumors.
Zhu Kangshun, director of the Minimally Invasive Intervention Department of the Second Affiliated Hospital of Guangzhou Medical University, said that due to the large individual differences of liver cancer patients and the high heterogeneity of tumors, one or two treatment methods are often incompetent for all patients. Methods, it is necessary to formulate individualized treatment plans and select appropriate treatment strategies according to individual differences of patients to improve long-term survival of patients.
It is reported that the new technology of yttrium [90Y] microspheres is suitable for: patients with unresectable or unwilling to undergo surgical resection and ablation of liver malignancies, including: patients with hepatocellular carcinoma, cholangiocarcinoma and metastatic liver cancer (such as colorectal cancer liver cancer) metastases, breast cancer liver metastases, pancreatic cancer liver metastases, etc.).
(Finish)